Product Description
Celivarone, a new noniodinated benzofuran derivative pharmacologically related to dronedarone and amiodarone, has been shown to have antiarrhythmic properties at a molecular level. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22171925/)
Mechanisms of Action: ADRB1 Blocker,Potassium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Celivarone](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Atrial Fibrillation|Atrial Flutter
Phase 2: Other|Atrial Fibrillation|Atrial Flutter